This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Effect of Sarpogrelate on Platelet Aggregation in Patients With Cerebral Infarction: Dose-responsive Clinical Pharmacology Study

This study has been completed.
Information provided by:
Mitsubishi Tanabe Pharma Corporation Identifier:
First received: September 4, 2005
Last updated: April 8, 2015
Last verified: April 2015

Sarpogrelate is an antiplatelet agent that decreases 5-hydroxytryptamine( 5-HT )levels in platelets via blockade of 5-HT2 receptors, has been used in atherosclerotic peripheral arterial disease.

The present double-blind controlled clinical pharmacology study was performed on 45 patients with cerebral infarction, who were given 75, 150, or 300 mg three times daily of sarpogrelate for 7 days in order to evaluate the dose-response relationship in terms of the precisely measured inhibition of platelet aggregation.

Condition Intervention Phase
Cerebral Infarction Drug: MCI-9042 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Effect of Sarpogrelate on Platelet Aggregation in Patients With Cerebral Infarction: Clinical-pharmacological Dose-response Study.

Further study details as provided by Mitsubishi Tanabe Pharma Corporation:

Primary Outcome Measures:
  • The maximum intensity of platelet aggregation on the last day of medication and as post-treatment percentage inhibition of the maximum intensity of platelet aggregation at baseline [(baseline - post-treatment )/baseline × 100 in each subject].

Enrollment: 46
Study Start Date: April 2004
Study Completion Date: January 2005
Primary Completion Date: January 2005 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: group L
25mg sarpogrelate
Drug: MCI-9042
Experimental: group M
50mg sarpogrelate
Drug: MCI-9042
Experimental: group H
100mg sarpogrelate
Drug: MCI-9042


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Cerebral infarction except cardiac source of embolism based on the NINDSⅢclassification
  2. Neurological signs persisting≧ 1 day from onset
  3. Defined onset of symptoms, and stable condition at the period of enrollment
  4. CT or MRI detection of responsible site
  5. age≧20
  6. Systolic pressure≦180 mmHg, Diastolic pressure≦110 mmHg
  7. The maximum intensity of platelet aggregation is above 15 % induced by serotonin (1µM) and epinephrine (3µM) on the day of prior to the first medication
  8. Written informed consent must be obtained from the patients before enrollment into the study

Exclusion Criteria:

  1. Functional outcome at randomization: Modified Rankin Scale=4, 5
  2. Previous or planned for vascular surgery to cerebral infarction
  3. History of intracranial hemorrhage
  4. History of systemic bleeding, or other history of bleeding diathesis or coagulopathy
  5. With severe complications ( renal or hepatic insufficiency, heart failure, hemopathy, and so on )
  6. Treating malignant tumor
  7. Pregnant or possibly pregnant women, or nursing mothers
  8. History of sarpogrelate sensitivity
  9. Previously entered in other clinical trials within 3 months
  10. Less than 3 months since any other clinical trial
  11. Judged by investigator to be unsuitable for the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00147303

Sponsors and Collaborators
Mitsubishi Tanabe Pharma Corporation
Study Chair: Shinichiro Uchiyama, MD Tokyo Women's Medical University
  More Information

Responsible Party: General Manager, Clinical Research Department I, Mitsubishi Tanabe Pharma Corporation Identifier: NCT00147303     History of Changes
Other Study ID Numbers: MCI9042-17
Study First Received: September 4, 2005
Last Updated: April 8, 2015

Additional relevant MeSH terms:
Molecular Mechanisms of Pharmacological Action
Cerebral Infarction
Pathologic Processes
Brain Infarction
Brain Ischemia
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases
Fibrinolytic Agents
Fibrin Modulating Agents
Platelet Aggregation Inhibitors
Serotonin Antagonists
Serotonin Agents
Neurotransmitter Agents
Physiological Effects of Drugs processed this record on August 18, 2017